



(11) **EP 2 311 506 A1**

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(43) Date of publication:
20.04.2011 Bulletin 2011/16

(51) Int Cl.:
A61L 27/00 (2006.01)

(21) Application number: **09802960.6**

(86) International application number:
PCT/JP2009/063438

(22) Date of filing: **28.07.2009**

(87) International publication number:
WO 2010/013717 (04.02.2010 Gazette 2010/05)

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR**
Designated Extension States:
AL BA RS

- **IKADA Yoshito**
Uji-shi
Kyoto 611-0011 (JP)
- **SAKAMOTO Yuki**
Ayabe-shi
Kyoto 623-8512 (JP)
- **MATSUDA Shojiro**
Ayabe-shi
Kyoto 623-8512 (JP)

(30) Priority: **29.07.2008 JP 2008195409**

(71) Applicant: **Gunze Limited**
Ayabe-shi, Kyoto 623-8511 (JP)

(72) Inventors:
• **MATSUMURA Goki**
Tokyo 160-0015 (JP)

(74) Representative: **Adam, Holger**
Kraus & Weisert
Patent- und Rechtsanwälte
Thomas-Wimmer-Ring 15
80539 München (DE)

(54) **BASE MATERIAL FOR REVASCULARIZATION**

(57) The present invention aims to provide a material for revascularization which enables the regeneration of a blood vessel at an extremely high efficiency by being transplanted into a defect of the blood vessel.

The present invention provides a tubular material for revascularization comprising a foamed body comprising a bioabsorbable material, a reinforcing member comprising a bioabsorbable material for reinforcing the foamed body, and a reinforcing yarn comprising a bioabsorbable

material for reinforcing the foamed body, wherein the reinforcing yarn and the reinforcing member are located at the center or outer face of the foamed body, the inner face thereof is the foamed body, the reinforcing yarn is wound around in a spiral-shaped, ring-shaped or X-shaped manner, and the reinforcing yarn comprises a glycolide-ε-caprolactone copolymer.

EP 2 311 506 A1

Description

TECHNICAL FIELD

5 **[0001]** The present invention relates to a material for revascularization which enables the regeneration of a blood vessel at an extremely high efficiency by being transplanted into a defect of the blood vessel.

BACKGROUND ART

10 **[0002]** Presently, those clinically used as artificial blood vessels are non-absorbable polymers such as Gore-Tex. Such artificial blood vessels can exhibit extremely similar physical properties to those of blood vessels and have achieved a certain result in short-term revascularization. However, an artificial blood vessel using a non-absorbable polymer has a problem that a foreign matter semi-permanently remains in the body and it results in easy formation of a blood clot and therefore it is necessary to continuously administer an anticoagulant or the like. Further, particularly in the case of
15 use for a child, there are problems that it is needed to undergo surgery again due to size mismatch as the child grows and that re-surgery is required because of calcification of the artificial blood vessel.

[0003] To deal with the problems, recently, methods for regeneration of tissues by so-called regenerative medical techniques have been tried. That is, trials for regenerating patient own tissues by utilizing the cell proliferation mechanism of the patient itself in the scaffold of an artificial blood vessel are performed by transplantation of the artificial blood vessel
20 which is easy to be penetrated with cells into a defect of a blood vessel.

[0004] In order to apply such a regenerative medical technique to a revascularization technique, the present inventors have developed a material for revascularization containing a foamed body including a bioabsorbable polymer and a reinforcing material including a bioabsorbable polymer as a core material incorporated in the foamed body (Patent Document 1). With respect to this material for revascularization, the foamed body becomes a scaffold where cells are
25 firmly bonded and the reinforcing material plays a role of keeping strength enough to stand the blood flow during the time until a blood vessel is regenerated after the transplantation and also plays a role as a reinforcing material standing sutura. Since both of the foamed body and the reinforcing material include bioabsorbable polymers, the materials are absorbed after revascularization and thus it is made no need to continuously use an anticoagulant or the like in the late term. Furthermore, it is also expected that the regenerated blood vessel can be grown since the regenerated blood
30 vessel is of own tissues. Actually, the material for revascularization has been regarded to be extremely significant in terms of clinical use. However, for actual clinical application, needless to say, a further improved revascularization efficiency and reliability have to be aimed.

PRIOR ART DOCUMENT

35

PATENT DOCUMENT

[0005] Patent Document 1: Japanese Kokai Publication 2001-78750 (JP-A 2001-78750) SUMMARY OF THE INVENTION
40

PROBLEMS TO BE SOLVED BY THE INVENTION

[0006] In the case where an artificial blood vessel is transplanted, whether blood vessel tissues can be regenerated or not depends on easiness of cell penetration into the artificial blood vessel and no coarctation occurrence until the
45 blood vessel tissues are regenerated. In order to make the penetration with cells easy, it is required for a material of the artificial blood vessel to be flexible and have a high water-absorbing property. On the other hand, in the tissue regeneration process, since coarctation is caused by tensile force of the proliferated cells toward the lumen, a tubular artificial blood vessel is required to have mechanical strength sufficient for preventing squeeze, that is, the tubular body is required to exhibit high compressive elasticity modulus when compressed and to keep the diameter. In such a manner, the flexibility
50 and high water-absorbing property and the high compressive elasticity modulus are in a trade-off relation and difficult to realize compatibility. Further, in the case where the compressive elasticity modulus of the artificial blood vessel is high for a long time, there is another problem, "calcification", that the regenerated blood vessel becomes hard. The present invention aims to provide a material for revascularization which is easy to be penetrated with cells, hard to be squeezed, and at the same time prevented from calcification and enables the regeneration of a blood vessel at an
55 extremely high efficiency by being transplanted into a defect of the blood vessel.

MEANS FOR SOLVING THE PROBLEMS

[0007] The present invention is a tubular material for revascularization comprising a foamed body comprising a bio-absorbable material, a reinforcing member comprising a bioabsorbable material for reinforcing the foamed body, and a reinforcing yarn comprising a bioabsorbable material for reinforcing the foamed body; wherein the reinforcing yarn and reinforcing member are located at the center or outer face of the foamed body, the inner face thereof is the foamed body, the reinforcing yarn is wound around in a spiral-shaped, ring-shaped or X-shaped manner, and the reinforcing yarn comprises a glycolide- ϵ -caprolactone copolymer.

[0008] Hereinafter, the present invention will be described in more detail.

[0009] The material for revascularization of the present invention includes a foamed body including a bioabsorbable material (hereinafter, simply referred to as "foamed body") a reinforcing member including a bioabsorbable material for reinforcing the foamed body (hereinafter, simply referred to as "reinforcing member"), and a reinforcing yarn including a bioabsorbable material for reinforcing the foamed body (hereinafter, simply referred to as "reinforcing yarn").

[0010] The above-mentioned foamed body plays a role as a scaffold where cells penetrate and are bonded and proliferated and tissues are regenerated.

[0011] The pore diameter of the foamed body is required to be such an extent that cells easily penetrate the pores and proliferate and at the same time blood leakage is scarcely caused in the case of transplantation into a defect of a blood vessel and concretely, the lower limit is preferably 5 μm and the upper limit is preferably 100 μm . If the pore diameter of the foamed body is less than 5 μm , the cells are sometimes impossible to penetrate the pores of the foamed body and if it exceeds 100 μm , blood leakage is sometimes caused in the case of transplantation. The lower limit of the pore diameter of the foamed body is more preferably 10 μm and the upper limit is more preferably 50 μm .

[0012] The average pore diameter of the above-mentioned foamed body is measured by a conventional method, for example, a mercury penetration method, an image analysis method, or the like.

[0013] The thickness of the foamed body is not particularly limited; however the lower limit is preferably 0.3 mm and the upper limit is preferably 1.5 mm. If the thickness of the foamed body is less than 0.3 mm, the compressive elasticity modulus is low and coarctation tends to be caused easily in some cases when the tubular body is compressed and if it exceeds 1.5 mm, the flexibility is deficient and the water absorption coefficient is lowered and cell penetration becomes difficult in some cases. The lower limit of the thickness of the foamed body is more preferably 0.4 mm and the upper limit is more preferably 1.2 mm.

[0014] Examples of the bioabsorbable material constituting the above-mentioned foamed body include polyglycolides, polylactides (D, L, or DL form), polycaprolactones, glycolide-lactide (D, L, or DL form) copolymers, glycolide- ϵ -caprolactone copolymers, lactide (D, L, or DL form)- ϵ -caprolactone copolymers, as well as polydioxanones, glycolide-lactide (D, L, or DL form)- ϵ -caprolactone copolymers, and the like. Particularly, lactide (D, L, or DL form)- ϵ -caprolactone copolymers are preferable. These bioabsorbable materials may be used alone or two or more of them may be used in combination.

[0015] The above-mentioned foamed body may be subjected to a hydrophilic treatment. The hydrophilic treatment makes the cell penetration easier.

[0016] The above-mentioned hydrophilic treatment is not particularly limited and examples thereof include plasma treatment, glow discharge treatment, corona discharge treatment, ozone treatment, surface graft treatment, ultraviolet radiation treatment, and the like. Particularly, plasma treatment is preferable since the treatment remarkably improves the water absorption coefficient without changing the appearance of the material for revascularization.

[0017] The above-mentioned reinforcing member plays a role of keeping strength enough to stand the blood flow and intravascular pressure (blood pressure) during the time until a blood vessel is regenerated after transplantation by reinforcing the foamed body as well as a role of improving suture retention ability at the time of suturing with the blood vessel.

[0018] The reinforcing member is not particularly limited if it has higher strength than that of the foamed body and examples thereof include a fibrous body, a nonwoven fabric-like body, a film-like body, and the like. Particularly, a fibrous body such as a weft knitted fabric, a warp knitted fabric, a braid or a woven fabric produced by knit and weave fibers including a bioabsorbable material is preferable.

[0019] Examples of the bioabsorbable material constituting the above-mentioned reinforcing member include polyglycolides, polylactides (D, L, or DL form), polycaprolactones, glycolide-lactide (D, L, or DL form) copolymers, glycolide- ϵ -caprolactone copolymers, lactide (D, L, or DL form)- ϵ -caprolactone copolymers, as well as polydioxanones, glycolide-lactide (D, L, or DL form)- ϵ -caprolactone copolymers, and the like. These bioabsorbable materials may be used alone or two or more of them may be used in combination. Further, the bioabsorbable material constituting the reinforcing member may be the same as or different from the bioabsorbable material constituting the foamed body.

[0020] The thickness of the fibers constituting the reinforcing member is not particularly limited; however, the lower limit is preferably 15 denier and the upper limit is preferably 500 denier. If the thickness of the fibers constituting the reinforcing member is less than 15 denier, suturing sometimes becomes impossible at the time of suturing with a blood

vessel of a living body and if it exceeds 500 denier, the above-mentioned reinforcing member cannot be produced in some cases. The lower limit of the thickness of the fibers constituting the reinforcing member is more preferably 20 denier and the upper limit is more preferably 450 denier.

[0021] The above-mentioned reinforcing yarn plays a role of reinforcing the foamed body and keeping strength enough to stand compression from the blood flow, lungs, and other organs in the surroundings and tensile force toward the lumen during the time until a blood vessel is regenerated after transplantation.

[0022] The reinforcing yarn may be a monofilament yarn and a multi-filament yarn and since having higher bending elasticity and excellent durability to compression force, the monofilament yarn is preferable.

[0023] The thickness of the reinforcing yarn is not particularly limited; however, the lower limit is preferably 0.2 mm and the upper limit is preferably 0.7 mm. If the thickness of the reinforcing yarn is less than 0.2 mm, the compressive elasticity modulus is low and coarctation tends to be caused easily in some cases when the tubular body is compressed and if it exceeds 0.7 mm, the flexibility is deficient and it sometimes results in difficulty for use as the material for revascularization. The lower limit of the thickness of the reinforcing yarn is more preferably 0.25 mm and the upper limit is more preferably 0.5 mm.

[0024] The bioabsorbable material constituting the reinforcing yarn is a glycolide- ϵ -caprolactone copolymer. The glycolide- ϵ -caprolactone copolymer is a relatively "hard" resin with an elasticity modulus of about 630 MPa and, on the other hand, has a half-life period of strength of 1 to 2 weeks and accordingly has a property that it is decomposed within a relatively short time to sharply decrease the strength. Use of the reinforcing yarn including the glycolide- ϵ -caprolactone copolymer provides sufficient strength for a while from the transplantation and prevents squeezing of the material for revascularization and coarctation of the blood vessel and on the other hand, the reinforcing yarn is decomposed and absorbed to lose the strength when a blood vessel is regenerated to a certain extent and further deposition of minerals can be prevented since the material does not remain and accordingly, "calcification" is efficiently prevented.

[0025] Further, owing to low compatibility of the glycolide- ϵ -caprolactone copolymer with the above-mentioned foamed body and its decomposition within a relatively short time, the glycolide- ϵ -caprolactone copolymer is supposed to be separated from the foamed body within a short time after transplantation. Use of the reinforcing yarn including the glycolide- ϵ -caprolactone copolymer provides sufficient strength for a while from the transplantation and prevents squeezing of the material for revascularization and coarctation of the blood vessel and on the other hand, the reinforcing yarn is separated from the foamed body when a blood vessel is regenerated to a certain extent. The foamed body from which the reinforcing yarn is separated can be expanded and contracted in accordance with proliferation of cells, so that the regeneration of a blood vessel is not inhibited. It is also supposed to result in efficient prevention of "calcification".

[0026] In addition, although the cause is not made clear, if the reinforcing yarn is subjected to coating or the like for improving the compatibility with the foamed body, it rather results in coarctation or the like in some cases. Accordingly, the above-mentioned reinforcing yarn is preferably one consisting of merely the glycolide- ϵ -caprolactone copolymer without being subjected to coating or the like.

[0027] The composition ratio of the glycolide- ϵ -caprolactone copolymer constituting the reinforcing yarn is preferably a ratio (mole ratio) of glycolide : ϵ -caprolactone of 90 : 10 to 45 : 55. If the ratio of glycolide exceeds 90, the reinforcing yarn becomes hard and brittle and is decomposed too fast and it is not preferable for regeneration of blood vessel tissues. On the other hand, if the ratio of ϵ -caprolactone exceeds 55, the reinforcing yarn becomes too much flexible, so that the reinforcing effect is small and further, the decomposing rate is retarded, so that it results in occurrence of "calcification".

[0028] With respect to a positioning relation between the foamed body and the reinforcing member, the reinforcing member is located at the center or outer face of the tubular body, which is the material for revascularization of the present invention, and the inner face of the tubular body is the above-mentioned foamed body. According to such a configuration, the reinforcing member can sufficiently play a roll of keeping strength and promote regeneration of a blood vessel from the inner side thereof to carry out early revascularization.

[0029] The above-mentioned reinforcing yarn is wound around such a composite of the foamed body and the reinforcing member in a spiral-shaped, ring-shaped or X-shaped manner. Arrangement of the reinforcing yarn in the above-mentioned state provides the material for revascularization to be obtained with further difficulty in squeezing. The reinforcing yarn may be located in the center of the foamed body or in the outer most face.

[0030] In the case where the reinforcing yarn is wound in a spiral-shaped or ring-shaped manner, the lower limit of the winding pitch is preferably 1 mm and the upper limit is preferably 10 mm. If the winding pitch of the reinforcing yarn is less than 1 mm, it sometimes becomes a cause of "calcification" or a cause of retardation of revascularization and if it exceeds 10 mm, it sometimes results in difficulty of attaining a sufficient reinforcing effect. The lower limit of the winding pitch of the reinforcing yarn is more preferably 2 mm and the upper limit is more preferably 8 mm.

[0031] The inner diameter and length of the tubular body, which is the material for revascularization of the present invention, may be selected in accordance with the aimed blood vessel.

[0032] The lower limit of the thickness of the material for revascularization of the present invention is preferably 0.3 mm and the upper limit is preferably 1.5 mm. If the thickness of the material for revascularization is less than 0.3 mm, it sometimes result in difficulty of attaining sufficient strength to stand the blood flow or sutura sometimes becomes

difficult and if it exceeds 1.5 mm, the time taken for absorption is vainly prolonged and it sometimes becomes a cause of calcification.

[0033] A method for producing the material for revascularization of the present invention is not particularly limited; however examples thereof include a method of installing the previously prepared reinforcing member in a mold, pouring and freezing a solution of a bioabsorbable material forming the foamed body in the mold, and thereafter freeze-drying the material (a freeze dry method); a method of attaching a mixed solution of a water-soluble substance and a bioabsorbable material forming the above-mentioned foamed body to the previously produced reinforcing member and then drying the solution, and thereafter washing out the water-soluble substance by water washing (an elution method); and the like. In the freeze dry method, foamed bodies having various pore diameters can be produced in accordance with the freezing temperature, the polymer concentration, or the like. In the elution method, the pore diameter of a foamed body can be controlled by adjusting the particles of a water-soluble substance.

[0034] Since the material for revascularization of the present invention is obtained by reinforcing a foamed body including a bioabsorbable material with a reinforcing member including a bioabsorbable material against the outward force and further reinforcing the foamed body with a reinforcing yarn including a bioabsorbable material against the inward force, the foamed body can be a scaffold where cells penetrate and are bonded and the reinforcing member and the reinforcing yarn play a role of keeping strength enough to stand the blood flow during the time until a blood vessel is regenerated after transplantation. On the other hand, since the bioabsorbable material constituting the reinforcing yarn is a glycolide- ϵ -caprolactone copolymer, decomposition occurs quickly and it does not cause "calcification".

[0035] The material for revascularization of the present invention can regenerate a blood vessel at an extremely high efficiency by being transplanted into a defect of the blood vessel.

[0036] At the time of transplantation, the material for revascularization of the present invention may be transplanted as it is. Even if the material for revascularization of the present invention is transplanted as it is without inoculation of cells, the foamed body of the material for revascularization of the present invention becomes a good scaffold and is penetrated easily with cells to regenerate a blood vessel.

[0037] Further, in the case where transplantation is carried out after previous inoculation of cells such as vascular endothelial cells, bone marrow cells, vascular smooth muscle cells and fibroblast cells, earlier revascularization can be expected.

EFFECTS OF THE INVENTION

[0038] The present invention provides a material for revascularization which enables the regeneration of a blood vessel at an extremely high efficiency by being transplanted into a defect of the blood vessel.

BRIEF DESCRIPTION OF THE DRAWINGS

[0039]

Fig. 1 is an image of a tissue section of the transplanted part of the material for revascularization obtained in Comparative Example 1 stained by Nishiyama method.

Fig. 2 is an incision image of the transplanted part after the material for revascularization obtained in Example 1 was transplanted and each sample was sacrificed after 13 months from the transplantation.

Fig. 3 is an image of the stained transplanted part after the material for revascularization obtained in Example 1 was transplanted and each sample was sacrificed after 13 months from the transplantation.

MODE FOR CARRYING OUT THE INVENTION

[0040] Hereinafter, aspects of the present invention will be described in more detail with reference to examples; however it is not intended that the present invention be limited to the examples.

(Example 1)

[0041] A plain-knitted fabric formed cylindrically by using a polyglycolide yarn with 140 denier was attached to a rod made of a fluororesin with an outer diameter of 10 mm. The rod to which the plain-knitted fabric was attached was immersed in a 4% by weight dioxane solution of an L-lactide- ϵ -caprolactone copolymer (mole ratio 50 : 50) and frozen at -80°C and thereafter subjected to freeze dry at -40°C to 40°C for 12 hours to obtain a foamed body. Next, while being reversed, the foamed body was separated from the rod made of a fluororesin and again attached to the rod made of a fluororesin. A monofilament yarn (thickness 1-0) of a glycolide- ϵ -caprolactone copolymer (ratio of glycolide : ϵ -caprolactone (mole ratio) 75 : 25) as a reinforcing yarn was wound in a spiral-shaped manner at 3 mm pitch around the surface

of the foamed body. The foamed body around which the monofilament yarn was wound was immersed in a 4% by weight dioxane solution of an L-lactide- ϵ -caprolactone copolymer (mole ratio 50 : 50) for 30 seconds and frozen at -80°C and thereafter subjected to freeze dry at -40°C to 40°C for 12 hours. A material for revascularization with a sandwich structure having a foamed layer with a thickness of 0.9 mm was obtained by the above-mentioned method.

(Comparative Example 1)

[0042] A material for revascularization was obtained in the same manner as in Example 1, except that a monofilament yarn (thickness 0.4 mm and USP size 1-0) of an L-lactide-s-caprolactone copolymer was used as a reinforcing yarn.

(Reference Example 1)

[0043] A material for revascularization was obtained in the same manner as in Example 1, except that a monofilament yarn (thickness 0.4 mm and USP size 1-0) of a glycolide- ϵ -caprolactone copolymer coated with an L-lactide- ϵ -caprolactone copolymer (mole ratio 50 : 50) was used as a reinforcing yarn.

[0044] In this connection, the coating was carried out by immersing the monofilament yarn of a glycolide- ϵ -caprolactone copolymer in the 4% by weight dioxane solution of an L-lactide- ϵ -caprolactone copolymer (mole ratio 50 : 50) and thereafter drying the monofilament yarn.

(In vitro evaluation)

[0045] The strength needed to compress each of the obtained tubular materials for revascularization until the diameter became 1/2 was measured. If the value is higher, it means that the material for revascularization has higher diameter retention force to coarctation.

[0046] Further, force of 200 g was repeatedly applied in the direction in which the diameter was compressed and the number of times until each of the materials for revascularization was transversely squeezed and could not keep the shape was measured.

[0047] The results are shown in Table 1.

[0048]

[Table 1]

	Reinforcing yarn	Winding method	Compressive elasticity modulus test	
			Force needed for 1/2 compression (g)	Number of times until shape could not be retained
Example 1	Glycolic acid- ϵ -caprolactone copolymer	Spiral-shaped manner	218	107
Comparative Example 1	L-lactide- ϵ -caprolactone copolymer	Spiral-shaped manner	320	153
Reference Example 1	Glycolic acid- ϵ -caprolactone copolymer (with coating)	Spiral-shaped manner	270	139

(Evaluation by animal experiment)

[0049] The materials for revascularization obtained in Example, Comparative Example, and Reference Example were evaluated by an animal experiment with the following method.

[0050] A portion of inferior vena cava of each beagle dog with a weight around 10 kg was resected and transplanted with each of the materials for revascularization obtained in Example, Comparative Example, and Reference Example. Eleven specimens were used for Example 1: four specimens for Comparative Example 1: and eight specimens for Reference Example 1 to carry out the experiment and the number of surviving specimens after 6 months from the transplantation was measured.

[0051] The configuration of the blood vessel was recorded by angiographic examination after 6 months from the transplantation and thereafter specimens were sacrificed and the occurrence of ascites was observed with eye observation. Further, the respective transplanted parts (regenerated blood vessel parts) were touched with fingers to evaluate the presence or absence of sclerosis lesions and also the presence or absence of calcification by macro observation. Furthermore, tissue sections were produced and histologically evaluated with a microscope and also the presence or absence of calcification was evaluated by Nishiyama method or von Kossa method.

[0052] The results are shown in Table 2.

[0053]

[Table 2]

	Reinforcing yarn	Winding method	Results of animal experiment			
			Number of surviving specimens after 6 months from transplantation	Presence or absence of coarctation	Presence or absence of ascites	Calcification
Example 1	Glycolic acid- ϵ -caprolactone copolymer	Spiral-shaped manner	11/11	None	None	None
Comparative Example 1	L-lactide- ϵ -caprolactone copolymer	Spiral-shaped manner	4/4	None	None	Occurred in all of 4 specimens
Reference Examples 1	Glycolic acid- ϵ -caprolactone copolymer (with coating)	Spiral-shaped manner	4/8	None	None	None

[0054] According to Table 2, in the case where the materials for revascularization of Example 1 and Comparative Example 1 were transplanted, the survival rate after 6 months from the transplantation was 100% and neither coarctation nor ascites was observed. However, in the case of using the material for revascularization of Example 1, no calcification was observed, whereas apparent calcification was observed for all of the specimens in the case of using the material for revascularization of Comparative Example 1. A tissue section of the transplanted part of the material for revascularization obtained in Comparative Example 1 was produced and an image of the tissue section stained by Nishiyama method was shown in Fig. 1. In Example 1, a good opening property of the blood vessel and production of tissues histologically extremely similar to those of a venous vessel were confirmed and no calcification was observed. In Comparative Example 1, calcification was observed and although a function as a duct was obtained; however there was a histological problem. Fig. 2 shows an incision image of the transplanted part after the material for revascularization obtained in Example 1 was transplanted and each sample was sacrificed after 13 months from the transplantation. Fig. 3 shows an image of the stained transplanted part.

[0055] In the case of transplantation of the material for revascularization of Reference Example 1, the survival rate after 6 months from the transplantation was 50% and specimens (4 dogs) survived for 6 months or longer after the transplantation were investigated to find neither coarctation nor ascites. However, in the case where the specimens died within 6 month from the transplantation were investigated, coarctation and ascites were observed in all of four dogs.

(Experimental Example)

[0056] Materials for revascularization were obtained in the same manner as in Example 1, except that the thickness of the monofilament yarn of a glycolide- ϵ -caprolactone copolymer to be used as the reinforcing yarn was changed to 1-0 (0.4 to 0.5 mm), 2-0 (0.35 to 0.4 mm), and 3-0 (0.25 to 0.3 mm) and the compressive elasticity modulus was evaluated.

[0057] The results are shown in Table 3.

[0058]

[Table 3]

Thickness of reinforcing yarn	Compressive elasticity modulus test (Force needed for 1/2 compression (g))
1-O	218
2-O	160
3-O	84

INDUSTRIAL APPLICABILITY

[0059] According to the present invention, a material for revascularization which enables the regeneration of a blood vessel at an extremely high efficiency by being transplanted into a defect of the blood vessel can be obtained.


Claims

1. A tubular material for revascularization comprising a foamed body comprising a bioabsorbable material, a reinforcing member comprising a bioabsorbable material for reinforcing said foamed body, and a reinforcing yarn comprising a bioabsorbable material for reinforcing said foamed body; wherein said reinforcing yarn and reinforcing member are located at the center or outer face of said foamed body, the inner face thereof is said foamed body, said reinforcing yarn is wound around in a spiral-shaped, ring-shaped or X-shaped manner, and said reinforcing yarn comprises a glycolide- ϵ -caprolactone copolymer.
2. The material for revascularization according to claim 1, wherein the foamed body comprises a lactide (D, L, or DL form)- ϵ -caprolactone copolymer.
3. The material for revascularization according to claim 1, wherein the reinforcing yarn is wound in a spiral-shaped manner.
4. The material for revascularization according to claim 1, wherein the reinforcing yarn and reinforcing member are located at the center of the foamed body.


[Fig. 1]



[Fig. 2]




Heart ⇌ Diaphragm



Heart ⇌ Diaphragm

[Fig. 3]



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2009/063438

A. CLASSIFICATION OF SUBJECT MATTER

A61L27/00 (2006.01) i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61L27/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2009

Kokai Jitsuyo Shinan Koho 1971-2009 Toroku Jitsuyo Shinan Koho 1994-2009

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAplus (STN), MEDLINE (STN), JSTPlus (JDreamII), JMEDPlus (JDreamII),
JST7580 (JDreamII)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/088042 A1 (Gunze Ltd.),	1-4
Y	24 July, 2008 (24.07.08), Full text; particularly, experimental example 6 & US 2008/0176206 A1	1-4
Y	JP 2005-185529 A (Gunze Ltd.), 14 July, 2005 (14.07.05), Full text; particularly, examples (Family: none)	1-4
Y	JP 2005-229906 A (Gunze Ltd.), 02 September, 2005 (02.09.05), Full text; particularly, example 1 (Family: none)	1-4



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 August, 2009 (21.08.09)

Date of mailing of the international search report

01 September, 2009 (01.09.09)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2009/063438

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JP 2005-34239 A (Gunze Ltd.), 10 February, 2005 (10.02.05), Full text; particularly, examples (Family: none)	1-4
Y	Lim S.H. et al., Tissue-engineered blood vessels with endothelial nitric oxide synthase activity, Journal of Biomedical Materials Research. Part B, Applied Biomaterials, 2008.05, Vol.85, No.2, pages 537 to 546, ISSN: 1552-4973	1-4
Y	Cho S.W. et al., Preliminary experience with tissue engineering of a venous vascular patch by using bone marrow-derived cells and a hybrid biodegradable polymer scaffold, Journal of Vascular Surgery, 2006, Vol.44, No.6, pages 1329 to 1340, ISSN: 0741-5214	1-4

Form PCT/ISA/210 (continuation of second sheet) (April 2007)

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP 2001078750 A [0005]